ivacaftor
Sign in to saveAlso known as VX-770, N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis. It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.
Key facts
- Drug.C
- 24
- Drug.H
- 28
- Drug.N
- 2
- Drug.O
- 3
- Drug.image
- Ivacaftor.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Kalydeco
- Drug.MedlinePlus
- a612012
- Drug.DailyMedID
- Ivacaftor
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- R07
- Drug.ATC_suffix
- AX02
- Drug.ATC_supplemental
- , , ,
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
2,263 papers- Elexacaftor/Ivacaftor/Tezacaftor: First Approval.Drugs · 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2019
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.American journal of respiratory and critical care medicine · 2022
- Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2014
- Cystic Fibrosis: A Review.JAMA · 2023
via PubMed
~11 min read
Encyclopedic overview
17 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Distribution
- Biotransformation
- Elimination
- History
- Society and culture
- Legal status
- Economics
- Research
- G551D mutation
- Other mutations
- References
- External links
Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis. It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.
Ivacaftor was approved by the US Food and Drug Administration (FDA) in January 2012. The combination drug lumacaftor/ivacaftor was approved by the FDA in July 2015. Ivacaftor, and the combination elexacaftor/tezacaftor/ivacaftor, are both on the World Health Organization's List of Essential Medicines.
Excerpted from Wikipedia’s “ivacaftor” article, available under the CC BY-SA 4.0 licence.